Automatic Dehumanization Across Menstrual Cycle

In the current study we address the role of hormonal fluctuations across menstrual cycle in female dehumanization of women and men. Using a sequential priming procedure in a lexical decision task, we test whether increased levels of conception risk lead to dehumanization of other women and men on both animal and human dimensions. Results showed that for word woman as the prime, animal words were more accessible in the high than in the low conception risk of the menstrual cycle; whereas human words were more inhibited in the high compared to the low conception risk. As for word man prime, no difference in terms of accessibility was found between the high and the low conception risk on both animaland human-words. This study demonstrates that dehumanization of women is automatically elicited by menstrual cycle–related processes and associated with women’s mate-attraction goals

Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study

Introduction: Besides data reported in a Phase-III trial, data on sunitinib in pancreatic Neuroendocrine Tumors (panNETs) are scanty. Aim: To evaluate sunitinib efficacy and tolerability in panNETs patients treated in a real-world setting. Patients and methods: Retrospective analysis of progressive panNETs treated with sunitinib. Efficacy was assessed by evaluating progression-free survival, overall survival, and disease control (DC) rate (stable disease (SD) + partial response + complete response). Data are reported as median (25th\ue2\u80\u9375th IQR). Results: Eighty patients were included. Overall, 71.1% had NET G2, 26.3% had NET G1, and 2.6% had NET G3 neoplasms. A total of 53 patients (66.3%) had received three or more therapeutic regimens before sunitinib, with 24 patients (30%) having been treated with four previous treatments. Median PFS was 10 months. Similar risk of progression was observed between NET G1 and NET G2 tumors (median PFS 11 months and 8 months, respectively), and between patients who had received \ue2\u89\ua5 3 vs \ue2\u89\ua4 2 therapeutic approaches before sunitinib (median PFS 9 months and 10 months, respectively). DC rate was 71.3% and SD was the most frequent observed response, occurring in 43 pts (53.8%). Overall, 59 pts (73.8%) experienced AEs, which were grade 1\ue2\u80\u932 in 43 of them (72.9%), grade 3 in 15 pts (25.4%), and grade 4 in one patient (1.7%). Six pts (7.5%) stopped treatment due to toxicity. Conclusions: The present real-world experience shows that sunitinib is a safe and effective treatment for panNETs, even in the clinical setting of heavily pre-treated, progressive diseases

Comparing group dehumanization and intra-sexual competition among normally ovulating women and hormonal contraceptive users

Two studies address the role of hormonal shift across menstrual cycle in female dehumanization of other women. In Study 1, normally ovulating women (NOW) and women who use hormonal contraceptives (HCW) are compared in terms of how much they dehumanize other women and two other control targets (men and elderly people). In NOW, the level of dehumanization of other women, but not of men and elderly people, increases as the conception risk is enhanced. HCW do not show this pattern of results. In Study 2, we investigate the level of dehumanization of other women and of intra-sexual competition. Findings concerning dehumanization replicate those of Study 1. Intra-sexual competition increases with the rise of conception risk only in NOW. In addition, dehumanization is significantly associated with intra-sexual competition in NOW but not in HCW. Together, these studies demonstrate that dehumanization of women is elicited by menstrual cycle–related processes and associated with women’s mate-attraction goals

Automatic female dehumanization across the menstrual cycle.

In this study, we investigate whether hormonal shifts during the menstrual cycle contribute to the dehumanization of other women and men. Female participants with different levels of likelihood of conception (LoC) completed a semantic priming paradigm in a lexical decision task. When the word \u2018woman\u2019 was the prime, animal words were more accessible in high versus low LoC whereas human words were more inhibited in the high versus low LoC. When the word \u2018man\u2019 was used as the prime, no difference was found in terms of accessibility between high and low LoC for either animal or human words. These results show that the female dehumanization is automatically elicited by menstrual cycle-related processes and likely associated with an enhanced activation of mate-attraction goals

Automatic female dehumanization across the menstrual cycle

In this study, we investigate whether hormonal shifts during the menstrual cycle contribute to the dehumanization of other women and men. Female participants with different levels of likelihood of conception (LoC) completed a semantic priming paradigm in a lexical decision task. When the word ‘woman’ was the prime, animal words were more accessible in high versus low LoC whereas human words were more inhibited in the high versus low LoC. When the word ‘man’ was used as the prime, no difference was found in terms of accessibility between high and low LoC for either animal or human words. These results show that the female dehumanization is automatically elicited by menstrual cycle-related processes and likely associated with an enhanced activation of mate-attraction goals

Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis

There is scant evidence about optimal management of poorly differentiated neuroendocrine carcinoma of the bladder (BNEC). We performed a multicenter retrospective study on BNEC patients from 13 Italian neuroendocrine-dedicated centers to analyze strategies associated with better outcomes. Mixed adeno-neuroendocrine carcinomas (MANEC) were included. We analyzed overall survival (OS) in the overall cohort, relapse-free survival (RFS) in radically operated patients and progression-free survival (PFS) in patients who received chemotherapy for metastatic disease. Fifty-one BNEC patients were included (male: 46, median age: 70 years). Overall, median OS was 16.0 months, radical tumor resection was performed in 37 patients (72.5%) and 11 of these (29.7%) also received peri-operative platinum-etoposide chemotherapy. Median OS was longer in patients with better performance status (PS) and in those with stage I-III disease at diagnosis compared to stage IV. Among patients who underwent radical tumor resection (N = 37), RFS was longer in patients with better PS and showed a trend towards a longer RFS in those treated with peri-operative chemotherapy than with surgery alone (11 vs. 6 months; p = 0.078). Among 28 patients receiving chemotherapy for metastatic disease, PFS was 5.0 months and there was a trend towards improved PFS in patients receiving carboplatin-etoposide chemotherapy compared to other regimens. A multivariate model unmasked a significant association between carboplatin-etoposide chemotherapy and risk for disease progression or death (HR: 0.39 (95%CI: 0.16-0.96) p = 0.040). Performance status might be associated with improved RFS in radically operated patients, while type of chemotherapy might affect PFS in patients receiving chemotherapy for metastatic BNEC